Company profile
ASSEMBLY BIOSCIENCES, INC.
NASDAQ:ASMBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IMDUSIRAN SODIUM | phase2 | — | 2 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (23)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05569941 | phase1 | completed | 2022-11-11 | 2023-04-12 | Assembly Biosciences | A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects |
| NCT03576066 | phase2 | completed | 2018-06-11 | 2019-07-05 | Assembly Biosciences | A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection |
| NCT03577171 | phase2 | completed | 2018-06-19 | 2019-06-21 | Assembly Biosciences | A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV) |
| NCT04781647 | phase2 | terminated | 2021-02-18 | 2022-12-02 | Assembly Biosciences | A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection |
| NCT04454567 | phase2 | terminated | 2020-11-11 | 2021-04-08 | Assembly Biosciences | A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors |
FDA applications (0)
No records yet.